00:17 , Jul 14, 2018 |  BC Extra  |  Politics & Policy

Democrats report on Novartis, Cohen inquiry

While Novartis AG (NYSE:NVS; SIX:NOVN) has admitted to bidding Michael Cohen for access to the Trump administration, the parties' relationship may have been more extensive than the pharma disclosed to the public, according to an...
20:07 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

EMA's CHMP recommends CAR Ts, rare disease therapies

EMA's CHMP recommended for approval Kymriah tisagenlecleucel and Yescarta axicabtagene ciloleucel, the first two CAR T therapies backed by the committee. CHMP also recommended a handful of other Orphan drug candidates, including Cablivi caplicizumab, a key...
20:00 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis returns rights for Aveo's preclinical cachexia program

Novartis AG (NYSE:NVS; SIX:NOVN) will return to Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) rights for AV-380 and other related growth differentiation factor 15 (GDF15) inhibitor antibodies, according to an SEC filing. Aveo granted Novartis exclusive, worldwide rights to...
19:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Adlai Nortye gets rights to buparlisib from Novartis

Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to develop and commercialize buparlisib,...
19:22 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Incyte's Jakafi meets in Phase II for steroid-refractory GvHD

Incyte Corp. (NASDAQ:INCY) said Jakafi ruxolitinib in combination with corticosteroids met the primary endpoint in the U.S. Phase II REACH1 trial to treat steroid-refractory acute graft-versus-host disease (GvHD). The company plans to submit an sNDA...
19:14 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Array reports Phase III OS data for encorafenib/binimetinib/Erbitux triple combo in mCRC

Array BioPharma Inc. (NASDAQ:ARRY) reported additional data from the safety lead-in portion of the open-label, international Phase III BEACON CRC trial showing that encorafenib (LGX818) plus binimetinib (MEK162) and Erbitux cetuximab led to a one-year...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis to spin out Alcon unit

Novartis AG (NYSE:NVS; SIX:NOVN) said it intends to spin out its Alcon eye care business, while retaining the pharma’s ophthalmology pharmaceuticals portfolio. The spinout will include Alcon’s surgical and vision care assets, which yielded $6.7 billion...
18:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Novartis' infigratinib leads to 25.4% ORR in urothelial carcinoma patients

Data from 67 patients with previously treated advanced urothelial carcinoma with fibroblast growth factor (FGF) receptor 3 (FGFR3; CD333) alterations in an expansion cohort of an open-label, international Phase I trial showed that once-daily 125...
18:55 , Jul 13, 2018 |  BC Week In Review  |  Company News

Kymriah deal to stay despite CMS shift on proposed pilot

Novartis AG (NYSE:NVS; SIX:NOVN) said on July 9 an outcomes-based contract for Kymriah tisagenlecleucel remains in effect with treatment centers. The contract is unaffected by CMS's decision not to pursue the pharma's proposal for a...
18:54 , Jul 13, 2018 |  BC Week In Review  |  Company News

Novartis drops antibiotic, antiviral research

Novartis AG (NYSE:NVS; SIX:NOVN) is exiting antibacterial and antiviral research, according to an emailed statement from the company. The pharma plans to cut headcount at the Emeryville, Calif., campus of Novartis Institutes for BioMedical Research (NIBR)...